Protagonist Therapeutics Inc (PTGX)

Net profit margin

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Net income (ttm)	US$ in thousands	275,188	170,849	169,954	162,110	-76,659	-135,279	-131,335	-133,506	-122,826	-128,448	-132,091	-122,302	-125,551	-107,530	-81,489	-70,068	-66,150	-64,765	-73,411	-83,164
Revenue (ttm)	US$ in thousands	434,433	323,795	319,120	314,953	60,000	0	0	859	26,581	35,198	45,484	46,890	27,357	24,390	27,218	31,170	28,628	25,697	16,724	2,318
Net profit margin		63.34%	52.76%	53.26%	51.47%	-127.76%	—	—	-15,542.03%	-462.08%	-364.93%	-290.41%	-260.83%	-458.94%	-440.88%	-299.39%	-224.79%	-231.07%	-252.03%	-438.96%	-3,587.75%

December 31, 2024 calculation

Net profit margin = Net income (ttm) ÷ Revenue (ttm)
= $275,188K ÷ $434,433K
= 63.34%

The analysis of Protagonist Therapeutics Inc's net profit margin reveals a fluctuating trend over the past few quarters. Initially, the company experienced significantly negative net profit margins, with figures ranging from -224.79% to -458.94%. These values indicate that the company was incurring substantial losses relative to its revenue during that period.

However, the situation improved somewhat in the later quarters of 2023 and early 2024, with the net profit margin showing a positive trend. By December 31, 2024, the net profit margin reached a healthy 63.34%, indicating that the company was able to generate a profit relative to its total revenue.

It is worth noting the significant improvement from the extremely negative figures seen earlier, signaling a potential turnaround in the company's financial performance. Further monitoring of the net profit margin will be essential to assess the company's sustainability and profitability in the long term.